Neurocrine Biosciences | NBIX - Zobowiązania





Zobowiązania Zmiana Data
AbbVie USD 43.1B 1.46B 2026-09
Acadia Pharmaceuticals USD 332.22M 29.22M 2026-09
Agios Pharmaceuticals USD 77.59M 7.37M 2026-09
ALKERMES USD 651.93M 10.16M 2026-09
Alnylam Pharmaceuticals USD 2.06B 550.49M 2026-09
Amgen USD 23.23B 2.27B 2026-09
Biogen USD 3.9B 18.7M 2026-09
BioMarin Pharmaceutical USD 1.6B 59.17M 2026-09
Cytokinetics USD 353.42M 171.99M 2026-09
Enanta Pharmaceuticals USD 44.73M 3.83M 2025-12
Exelixis USD 411.88M 49.95M 2026-09
Gilead Sciences USD 12B 982M 2026-09
Halozyme Therapeutics USD 476.09M 131.65M 2026-09
Incyte USD 1.44B 125.72M 2026-09
Ionis Pharmaceuticals USD 315.64M 401.36M 2026-06
Nektar Therapeutics USD 57.71M 4.17M 2026-03
Neurocrine Biosciences USD 984.6M 110.1M 2026-09
Pfizer USD 31.73B 920M 2026-09
Prothena USD 11.43M 224K 2026-09
Regeneron Pharmaceuticals USD 6.2B 671.5M 2026-09
Repligen USD 125.69M 6.97M 2026-09
Rigel Pharmaceuticals USD 94.4M 7.76M 2025-09
Sarepta Therapeutics USD 656.35M 153.44M 2026-09
Teva Pharmaceutical Industries USD 15.42B 221M 2026-09
Ultragenyx Pharmaceutical USD 389M 38M 2026-09
Vertex Pharmaceuticals USD 5B 1.06B 2026-09